Progressive Oncology: Free Drugs, Shared Vials and Unadministered Doses

In the Progressive Oncology settlement, the Frederick, Maryland practice and its owner agreed to pay $1.45 million to resolve allegations of billing for free chemotherapy, shared single-use vials and drugs never administered. If you received the stock, prepared the doses or handled the claims, the allegations reach from the stockroom to the infusion chair to the claim sent for payment.

Progressive Oncology & Hematology offered chemotherapy services, and its owner was also its sole provider. The Justice Department’s July 1, 2026 announcement described claims to Medicare, Medicaid and the Department of Veterans Affairs for drugs the defendants had obtained at no expense. It also described the separate allegations about shared vials and prescribed drugs never given to patients.

The U.S. Attorney’s Office for the District of Maryland handled the case. The Health and Human Services Office of Inspector General and the Veterans Affairs Office of Inspector General investigated the billing.

Free Chemotherapy From Charities or Grant Programs

The government alleged that Progressive Oncology and its owner sought reimbursement for chemotherapy supplied free by charitable organizations or grant programs for specific patients. That is the central issue in the free-drug billing allegation: where the medication came from and what the practice asked the government to pay for.

Buy-and-bill connects the practice’s acquisition of a drug to its inventory, administration and claims. The drug and the work of administering it are separate payment components under the Medicare drug-payment framework. The usual drug price is based on manufacturers’ average sales prices, not the practice’s invoice. That makes the no-cost delivery record important: the reimbursement rate alone cannot tell us whether the practice bought the drug it billed.

We connect the purchase or no-cost delivery, the patient designation, the inventory entry and the administration record to the drug claim. We also want to understand who knew the source of the medication when the claim went out.

We see the absurdity in the government’s allegation: charity supplied the drug, and the practice asked taxpayers to pay for it. Help for the patient became a billing opportunity for the practice.

Alleged Single-Use Vial Wastage Split Across Patients

The government also alleged that Progressive Oncology and its owner directed that wastage from a single-use vial intended for one patient be split across two or more patients. The defendants allegedly submitted claims as though each patient had received a separate single-use vial. One vial. Several bills. That is the mismatch the government alleged.

The single-use vial and drug-waste records connect the dose order, vial size, administration, discarded amount and claim units. Medicare’s discarded-drug guidance addresses eligible medication discarded from a single-dose container. Under that guidance, overfill and quantities already paid through rounding do not create additional payable single-dose waste.

We follow the vial across the patients whose claims draw on it, including any amount represented as waste. An insider who can explain how staff divided the contents connects those patient claims to the same supply. That connection matters when each bill represents a separate vial.

Ophthalmic Consultants faced a similar allegation involving single-use Lucentis and Eylea vials. In its June 30, 2020 settlement announcement, the government alleged that multiple-patient use produced bills for more drug than the practice purchased. The shared question is concrete: how much drug came into the practice, how much reached patients and how much appeared on the bills?

Chemotherapy Allegedly Billed but Never Given

The third Progressive Oncology allegation concerned chemotherapy the physician prescribed but never administered to patients at the practice. The government alleged that the practice and its owner nonetheless billed federal and state health insurance programs for those drugs. Here, the treatment itself is the missing link between the prescription and the claim.

Infusion times show the work of giving a drug. They do not show how much drug was given. We examine the order, the administration record and the transmitted drug claim together, with the person who can explain what happened to the planned dose.

What Evidence Does a Whistleblower Need?

The useful evidence connects what the practice obtained and administered to what it billed a government program. In this case, the three allegations point to different comparisons: no-cost supply against drug reimbursement, shared vial contents against claimed quantities, and prescribed treatment against actual administration. The records behind a physician billing claim become more useful when someone can explain how they were created and used.

The 2017 Journal of AHIMA article Busting Bad Medicine: a Call to Action Addressing Healthcare, Fraud, Waste, and Abuse describes reviewing treatment dates, treatment types and clinical signatures when examining false billing. It also emphasizes that investigators need witnesses who can explain what they know, beyond the documentation itself. That is why the person who received a free shipment or prepared a dose may add something the claim alone cannot show.

Your knowledge may explain how a supply record became a charge, or why a prescribed drug appeared on a bill despite never reaching the patient. We bring that account together with the records, so the case tells the story of the medication and the government money claimed for it.

A physician practice qui tam case gives an insider a way to pursue false claims for government money. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We build the case with you by connecting the drug records to the billing decisions and the people who made them.

The Drug You Handled, the Claim You Question

If you know which chemotherapy arrived free, how a vial was divided or why a billed dose was never given, talk with our whistleblower experts about what you saw. We build the case with you around those differences and bring in healthcare fraud whistleblower lawyers who understand oncology drug billing. You have a partner from the first conversation through the pursuit of the case.